Eli Lilly and Company shares rose 4.5% after the drugmaker disclosed full results for its obesity agent retatrutide during presentations at the American Diabetes Association conference held over the weekend.
At a symposium on Saturday, Eli Lilly presented detailed findings from two Phase 3 trials. The TRANSCEND-T2D-1 trial examined retatrutide in treatment-naive patients with type 2 diabetes, while TRIUMPH-1 enrolled participants with overweight or obesity who did not have type 2 diabetes.
In TRIUMPH-1, participants receiving the 4 mg dose of retatrutide - a dose that requires only one titration step - recorded weight loss outcomes that exceeded those reported in the STEP 1 study of semaglutide. Those TRIUMPH-1 results were also within 4% of the outcomes observed at the maximum 15 mg dose of tirzepatide in the SURMOUNT 1 trial.
Analysts noted that the presentations met expectations for the molecule and did not introduce new safety concerns. The first Phase 3 trial's headline data were previously disclosed in late May; however, the schedule did not allow for simultaneous publication in a scientific journal due to timing constraints.
Later on Saturday evening, at an investor event, Eli Lilly outlined plans for its broader cardiometabolic product portfolio. The company indicated that its long-acting amylin analog, eloralintide, may develop into one of the largest Phase 3 programs in its pipeline. Management said combination data assessing eloralintide together with tirzepatide are expected to be released later this year.
The companys tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, has been gaining market share against Novo Nordisks competing products Ozempic and Wegovy in the United States, and, as of the first quarter of 2026, outside the United States as well.
The weekend disclosures appear to have reinforced investor confidence in Eli Lillys obesity strategy, driven both by retatrutides Phase 3 performance and by the expansion of adjunct programs such as eloralintide. The companys communication around upcoming combination data and an expanding cardiometabolic portfolio framed the presentations for investors and analysts alike.
While the presentations brought more complete data into the public domain, the company and market observers remain bound to the data and timelines provided by the firm; no additional safety signals were reported during the disclosed sessions.